A Japanese family with atypical type I familial amyloidotic polyneuropathy (FAP) in Iiyama, Japan was studied. Most of the family members have dysfunctions of the central nervous system, in addition to typical symptoms of type I FAP. The transthyretin (TTR, also called prealbumin) gene of the atypical FAP(FAP-IY) was analyzed with recombinant DNA techniques and a RIA method. FAP-IY was found to have the mutation responsible for the methionine-for-valine substitution at position 30 of TTR, as in the case of typical type I FAP. However, analysis of DNA polymorphisms in the TTR locus showed that FAP-TY has a genetic background differing from that of the typical type I FAP. These observations lead to the consideration that a genetic factor(s) involved in the dysfunction of the central nervous system may locate in a chromosome region in close proximity to the TTR gene.
Introduction
Familial amyloidotic polyneuropathy (FAP)' is a dominantly inherited disorder characterized by systemic deposition of amyloid fibrils, and is clinically classified into four types (1) . Type I FAP is the most common type and is manifested by sensory dissociation and autonomic involvement followed by motor neuropathy. Amyloid fibrils of type I FAP of Portuguese (2, 3) , Japanese (4, 5) , and Swedish (6, 7) origins contain a variant of transthyretin (TTR, also called prealbumin) with an amino acid substitution at position 30 (methionine-for-valine, 30vml _ Met) as a major component. Analysis ofnormal and patient types of TTR gene revealed that the 30v, _. Met substitution is caused by a single base change G --A and that this is the only base change specific for type I FAP in the TTR gene (8) (9) (10) . These findings led to the establishment of diagnostic methods for FAP using RIA (1 1), immunoblotting procedure 30vm a Met, methionine-for-valine substitution at position 30. (12), and recombinant DNA techniques (8, 13) . It became clear that type I FAP is a molecular disorder of TTR.
The disease process of type I FAP is not well understood at the molecular level. One approach to this issue may be a careful analysis of atypical FAP compared with the typical form. Such a study should provide a clue to genetic or other factors involved in the disease process. FAP families with variant TTR having amino acid substitutions other than the 30va1 -. Met change have been reported (14) (15) (16) (17) . An atypical FAP family has been detected in Iiyama, Japan (18, 19 (18, 19) . These observations raise the possibility that FAP-IY is a new phenotype of FAP (18 (18, 19) .
The pedigree of this family and the clinical features are given in Fig. 1 . Information was obtained for the 30 members, and 18 were available for clinical examination. Details of the neurological signs are summarized in Fig. 1 . Peripheral neuropathy was present in 1 1, and there were 11 with signs of CNS involvement, such as cerebellar signs (dysarthria, impaired finger-to-nose testing, dysdiadochokinesia, and ataxic gait) and hyperreflexia. Babinski's sign was present in five (11-6, 11-9, III-1, III-10, III-1 1).
Preparation of high-molecular weight DNA and blotting experiments. Peripheral blood samples (10-20 ml) were obtained from available members of the FAP-IY family (IV-1, IV-2, IV-3, 111-10, 111-11, V-1), and high-molecular weight DNA was prepared from white blood cells by the procedure of Ryan et al. (20) with minor modifications. Southern blotting was carried out as described by Maniatis et al. (21) . Unless noted, the cDNA clone pHH64-1 was used as the probe. A polymorphic base change that does not result in restriction site polymorphism was identified using a pair of oligonucleotide probes (5' TGCTATAGTAACTCCCTCT 3' and 5' TGCTATAGT-CACTCCCTCT 3') after the specific DNA region had been enzymatically amplified using a set of primers (5' GGGTCTGGATG-TAGTTCTGA 3' and 5' GTAATGTACCATACATAGGG 3'), according Saiki et al. (22 (Fig. 2 A) . These fragments were ligated to X gtWES arm DNA and packaged into phage particles by the in vitro packaging reaction (21) . Phages were grown on L-agar plates, with Escherichia coli K12 (LE392) as the host. -6.0 X 10 independent clones were obtained. The DNA library was screened by the plaque hybridization technique (23) using 32P-labeled DNA fragments from human cDNA (pHH64-1) (8) as the probe, and five clones carrying Eco RI 9-kb fragment and three clones of 4.89-kb fragment were obtained.
Nucleotide sequence analysis. Recombinant phage DNA was digested with restriction endonuclease, and DNA fragments to be sequenced were subcloned into the plasmid pUC 9. The nucleotide sequence was determined by the dideoxy chain termination method described by Hattori and Sakaki (24) . RIA (49Thr -Gly) (17), alanine for threonine at 60 (60Thr Ala) (16), and serine for isoleucine at 84 (8411e _ ser.) (14) . Mutations responsible for these amino acid substitutions (except 49Thr --Gly) can be detected by Southern blotting, using appropriate restriction enzymes: 30Val --Met by Nsi I, Bal 1 (8, 13) and 33Phe_ lle by Bcl 12 using pHH64-1 as a probe, and 60Thr --Ala by Pvu 11 (16) and 8411,e _ ser by Alu 12 using the 0.88-kb Alu I fragment (from position 3,844 to 4,728 [10] ) as a probe. DNA from FAP-IY patients were digested with these restriction enzymes and subjected to Southern blotting analysis. As shown in Fig. 2 (10) . The structure of the TTR gene is schematically shown in Fig. 3 . Clones carrying the 9.0-kb and 4.89-kb Eco RI fragments that cover most of the TTR gene (10) were isolated from a genomic DNA library of a FAP-IY patient (III-10), as described in Methods. As the patient is heterozygous for the mutation, the Eco RI fragments can be derived from both normal and mutant chromosomal genes. Two types of the 4.89-kb Eco RI fragments were cloned, based on the polymorphisms of Fnu 4H1I site at position 5,610 (for position numbers, see references 9 and 10). Two types of the 9.0-kb fragment (with and without Nsi I site at exon 2) were also cloned. The nucleotide sequences ofthese four fragments (two 9.0 kb and two 4.89 kb) were determined. Sequenced regions are indicated at the bottom of Fig. 3 the serum levels of the variant TTR. These levels are close to the value in typical type I FAP patients (9.18±2.69 mg/dl) (26). A family member carrying the mutation (V-I) also showed a similar level ofthe variant TTR long before the onset of the disease (Fig. 2 B) (9, 27) . Our previous work showed that there are six polymorphic base changes in the TTR gene region (9) . Among them, the association of T or G change at nucleotide position 1,218 and G or A (Msp I site + or -) change at position 2,537 to the G or A change at position 1,679 responsible for the 30vw substitution in exon 2 was examined. At first, DNA was digested with both Bal I and Msp I, which makes the four types of haplotypes distinguishable by length of the restriction fragments (Fig. 4 A) . The blotting profiles of FAP-IY families are shown in Fig. 4 family with FAP-TY has a genetic background differing from that of the typical type I FAP families in Japan.
Discussion
Although the most common type of hereditary generalized amyloidosis in Japan is type I FAP (28, 29) , a family of atypical type I FAP (FAP-IY) with CNS involvement has been found in Iiyama. The most remarkable feature of FAP-IY is the disorder of the CNS: cerebellar signs of dysarthria, incoordination in limbs, ataxic gait, and pyramidal tract signs. Although the patient IV-has at present a peripheral neuropathy (Fig. 1) , the symptom of CNS involvement may appear in the future. For example, the Babinski's sign has recently become evident in patients III-10 and III-I 1 (unpublished data). 
The nucleotide sequence of TTR gene has been published by our group (10) and by others (33). The numbering system for base positions by reference 10 is employed in this work. Although the sequence in reference 10 was revised after its publication (filed in GenBank DNA data base), the original numbering system has been employed to avoid confusion. Even We analyzed the structure and expression of FAP-IY TTR gene using recombinant DNA techniques and an RIA method and found that the FAP-IY patients carry the mutation responsible for the 30va --Met substitution as in the case oftypical type I FAP. No significant difference was observed in quality and quantity ofthe variant TTR in serum between typical type I FAP and FAP-IY. These findings suggested that a certain factor(s) other than the TTR gene is involved in the dysfunction of the CNS characteristic for FAP-IY. As shown in Fig. 1 , seven of 11 patients with peripheral neuropathy had obvious signs of CNS involvement, that is, the cerebellar signs and/or Babinski's sign (11-6, 9, III-1, 3, 8, 10, 1 1) . The remaining three (111-6, 9, 12) had a hyperreflexia. Thus, symptoms of type I FAP appear to be closely associated with dysfunction of the CNS in this family. The association of peripheral neuropathy with CNS involvement has not been detected in other FAP families in Japan. These findings suggested that such a factor(s) is genetically determined.
It is conceivable that FAP-IY is a combination of type I FAP and some hereditary disorders ofthe CNS. FAP-IY shares clinical features (cerebellar ataxia and pyramidal tract signs) with familial cerebellar ataxia and cerebrovascular amyloid (30) , and also with hereditary spinocerebellar degeneration (SCD). Ikeda et al. (18) pointed out that the computerized tomography scan imaging of FAP-IY patients shared findings similar to those with SCD, although no patient with FAP-IY has been autopsied. FAP patients in Japan number -1,000-2,000 and the prevalence of SCD (containing hereditary type and sporadic type) is roughly 1-7/100,000; Thus, the probability of a combination of these two diseases in one family would be extremely low, but not zero. Alternatively, the variant TTR with the 30val -_ Met substitution may directly cause dysfunction of the CNS in the presence of different genetic backgrounds. Further clinical and pathological studies will be required to determine the molecular basis of the dysfunction of the CNS. The genetic factor(s) involved in the dysfunction of CNS, if present, is probably linked to the TTR gene, which is assigned to ql 1.2-12.1 of chromosome 18 (31, 32) .
In conclusion, we obtained evidence that FAP-IY has the same mutation as type I FAP in the TTR gene. A genetic factor(s) involved in the dysfunction of the CNS may locate in a chromosomal region in close proximity to the TTR gene.
